(INMD) InMode - Overview
Stock: Medical Devices, Aesthetic Treatments, Skin Tightening, Fat Reduction
| Risk 5d forecast | |
|---|---|
| Volatility | 43.6% |
| Relative Tail Risk | -9.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.67 |
| Alpha | -43.07 |
| Character TTM | |
|---|---|
| Beta | 0.966 |
| Beta Downside | 1.395 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.28% |
| CAGR/Max DD | -0.33 |
EPS (Earnings per Share)
Revenue
Description: INMD InMode March 02, 2026
InMode Ltd. (NASDAQ: INMD) is an Israeli-based medical-technology firm that designs, develops, manufactures, and markets minimally invasive aesthetic devices using proprietary radio-frequency (RF) lipolysis and deep subdermal fractional RF technologies.
The company’s product suite spans invasive solutions for liposuction with simultaneous skin tightening, body and facial contouring, and ablative skin rejuvenation, as well as non-invasive offerings for permanent hair reduction, wrinkle and cellulite treatment, and vascular lesion removal. It also provides hands-free devices for skin tightening, fat reduction, and muscle stimulation.
InMode distributes its devices across North America, Europe, Asia-Pacific and emerging markets through a network of regional distributors, covering key territories such as the United States, Canada, the United Kingdom, Germany, France, Japan, Australia and India.
Recent performance highlights include Q3 2024 revenue of $120 million, up 22% year-over-year, and a gross margin of 78%, reflecting strong pricing power and demand for RF-based aesthetic solutions. The company entered Q4 2024 with $250 million of cash and short-term investments, providing runway for R&D and international expansion. The global aesthetic-device market is projected to grow at a ~10% CAGR through 2028, driven by rising disposable income, an aging-but-active population, and increasing consumer acceptance of minimally invasive cosmetic procedures.
For deeper insight, consider reviewing ValueRay’s detailed valuation model.
Headlines to watch out for
- Minimally invasive aesthetic product sales drive revenue growth
- Research and development spending impacts profitability
- Regulatory approvals affect market access and product launches
- Global economic conditions influence discretionary consumer spending
- Competition in aesthetic device market pressures pricing
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 93.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -5.14 > 1.0 |
| NWC/Revenue: 169.5% < 20% (prev 163.3%; Δ 6.20% < -1%) |
| CFO/TA 0.12 > 3% & CFO 90.4m > Net Income 93.8m |
| Net Debt (-289.3m) to EBITDA (104.2m): -2.78 < 3 |
| Current Ratio: 9.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.1m) vs 12m ago -11.96% < -2% |
| Gross Margin: 78.54% > 18% (prev 0.80%; Δ 7.77k% > 0.5%) |
| Asset Turnover: 47.74% > 50% (prev 50.25%; Δ -2.51% > 0%) |
| Interest Coverage Ratio: -15.09 > 6 (EBITDA TTM 104.2m / Interest Expense TTM -6.86m) |
Altman Z'' 10.00
| A: 0.82 (Total Current Assets 698.6m - Total Current Liabilities 70.7m) / Total Assets 766.4m |
| B: 1.26 (Retained Earnings 968.5m / Total Assets 766.4m) |
| C: 0.13 (EBIT TTM 103.5m / Avg Total Assets 776.0m) |
| D: 11.64 (Book Value of Equity 968.9m / Total Liabilities 83.2m) |
| Altman-Z'' Score: 22.61 = AAA |
Beneish M -2.83
| DSRI: 1.28 (Receivables 49.3m/41.1m, Revenue 370.5m/394.8m) |
| GMI: 1.02 (GM 78.54% / 80.31%) |
| AQI: 0.97 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 0.94 (Revenue 370.5m / 394.8m) |
| TATA: 0.00 (NI 93.8m - CFO 90.4m) / TA 766.4m) |
| Beneish M-Score: -2.83 (Cap -4..+1) = A |
What is the price of INMD shares?
Over the past week, the price has changed by -0.07%, over one month by -11.10%, over three months by -6.24% and over the past year by -26.59%.
Is INMD a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.8 | 24.2% |
| Analysts Target Price | 16.8 | 24.2% |
INMD Fundamental Data Overview March 17, 2026
P/E Forward = 8.6655
P/S = 2.3155
P/B = 1.2557
P/EG = 2.9004
Revenue TTM = 370.5m USD
EBIT TTM = 103.5m USD
EBITDA TTM = 104.2m USD
Long Term Debt = 8.23m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.22m USD (from shortTermDebt, last quarter)
Debt = 13.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -289.3m USD (from netDebt column, last quarter)
Enterprise Value = 315.8m USD (857.9m + Debt 13.2m - CCE 555.3m)
Interest Coverage Ratio = -15.09 (Ebit TTM 103.5m / Interest Expense TTM -6.86m)
EV/FCF = 3.53x (Enterprise Value 315.8m / FCF TTM 89.4m)
FCF Yield = 28.31% (FCF TTM 89.4m / Enterprise Value 315.8m)
FCF Margin = 24.13% (FCF TTM 89.4m / Revenue TTM 370.5m)
Net Margin = 25.33% (Net Income TTM 93.8m / Revenue TTM 370.5m)
Gross Margin = 78.54% ((Revenue TTM 370.5m - Cost of Revenue TTM 79.5m) / Revenue TTM)
Gross Margin QoQ = 78.28% (prev 77.61%)
Tobins Q-Ratio = 0.41 (Enterprise Value 315.8m / Total Assets 766.4m)
Interest Expense / Debt = 24.85% (Interest Expense 3.29m / Debt 13.2m)
Taxrate = 13.64% (4.27m / 31.3m)
NOPAT = 89.4m (EBIT 103.5m * (1 - 13.64%))
Current Ratio = 9.88 (Total Current Assets 698.6m / Total Current Liabilities 70.7m)
Debt / Equity = 0.02 (Debt 13.2m / totalStockholderEquity, last quarter 683.2m)
Debt / EBITDA = -2.78 (Net Debt -289.3m / EBITDA 104.2m)
Debt / FCF = -3.24 (Net Debt -289.3m / FCF TTM 89.4m)
Total Stockholder Equity = 646.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.09% (Net Income 93.8m / Total Assets 766.4m)
RoE = 14.52% (Net Income TTM 93.8m / Total Stockholder Equity 646.1m)
RoCE = 15.81% (EBIT 103.5m / Capital Employed (Equity 646.1m + L.T.Debt 8.23m))
RoIC = 13.08% (NOPAT 89.4m / Invested Capital 683.2m)
WACC = 9.66% (E(857.9m)/V(871.1m) * Re(9.48%) + D(13.2m)/V(871.1m) * Rd(24.85%) * (1-Tc(0.14)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -13.60%
[DCF] Terminal Value 71.05% ; FCFF base≈106.4m ; Y1≈99.7m ; Y5≈92.5m
[DCF] Fair Price = 24.29 (EV 1.25b - Net Debt -289.3m = Equity 1.54b / Shares 63.4m; r=9.66% [WACC]; 5y FCF grow -8.12% → 2.90% )
EPS Correlation: -44.62 | EPS CAGR: 3.80% | SUE: 0.59 | # QB: 0
Revenue Correlation: -35.27 | Revenue CAGR: 5.18% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-5 | Analysts=7
EPS current Year (2026-12-31): EPS=1.45 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-6 | Growth EPS=-9.6% | Growth Revenue=-0.2%
EPS next Year (2027-12-31): EPS=1.54 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-5 | Growth EPS=+6.3% | Growth Revenue=+4.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 9.5% - Earnings Yield 10.6%)
[Growth] Growth Spread = -1.5% (Analyst -2.5% - Implied -1.1%)